

SEC Number : CS201506626
File Number : _____

ALLIED CARE EXPERTS (ACE) DUMAGUETE DOCTORS INC.

(Company's Full Name)

DML Building, Northroad, Dumaguete City
(Company's Address)

008-997-532-000
(TIN Number)

(035) 421-2119
(Telephone Number)

-
(Fax Number)

SEC FORM 20-IS **DEFINITIVE INFORMATION STATEMENT**

Form Type

Each Active Secondary License Type and File Name: NONE

**SECURITIES AND EXCHANGE COMMISSION
SEC FORM 20-1S
INFORMATION STATEMENT PURSUANT TO SECTION 20
OF THE SECURITIES REGULATION CODE**

1. Check the appropriate box:

- ☐ Preliminary Information Statement
☒ Definitive Information Statement

2. Name of Registrant as specified in its charter: **ALLIED CARE EXPERTS (ACE) DUMAGUETE DOCTORS INC.**

3. Province, country or other jurisdiction of incorporation or organization: **Negros Oriental, Philippines**

4. SEC Identification Number: **CS201506626**

5. BIR Tax Identification Code: **008-997-532-000**

6. Address of Principal Office: Postal Code:

DML Building, Northroad, Dumaguete City **6200**

7. Registrant's telephone number, including area code: (035) 421 2119

8. Date, time and place of the meeting of security holders:

Date : **July 3, 2025**
Time : **8:00 a. m.**
Place : **F. Cimafranca St., Daro, Dumaguete City**
Via Zoom Webinar

9. Approximate date on which the Information Statement is first to be sent or given to security holders:
June 10, 2025

10. In case of Proxy Solicitations: NOT APPLICABLE

Name of Person Filing the Solicitation Statement:
Address and Tel. No. :

11. Securities registered pursuant to Section 8 and 12 of the Code or Section 4 and 8 of the RSA

Title of Each Class	Number of Shares of Common Stock Outstanding/ Amount of Debt Outstanding
Common Shares	As at March 31, 2025 – P168,600,000.00
Amount of Outstanding Debt	As at March 31, 2025 – P149,500,000.00

12. Are any or all registrant's securities listed in a Stock Exchange?

Yes _____ No x

PART I

INFORMATION REQUIRED IN INFORMATION STATEMENT

A. GENERAL INFORMATION

Date, time and place of meeting of security holders.

(a) The stockholders' meeting shall be held on:

Date : **July 3, 2025**
Time : **8:00 a. m.**
Place : **F. Cimafranca St., Daro, Dumaguete City**
Via Zoom Webinar

Complete Mailing Address of Principal Office of Registrant:

ALLIED CARE EXPERTS (ACE) DUMAGUETE DOCTORS INC.

DML Building, Northroad, Dumaguete City

The approximate date on which the information statement is first to be sent and given to security holders shall be **June 10, 2025**.

Dissenter's Right of Appraisal

There are no matters or proposed corporate actions included in the Agenda of the meeting which may give rise to a possible exercise by security holders of their appraisal right. Generally, however, under Section 80, Title X of the Revised Corporation Code of the Philippines, the stockholders of the Corporation have the right of appraisal under the following instances:

- a. In case an amendment to the articles of incorporation has the effect of changing or restricting the rights of any stockholder or class of shares, or of authorizing preferences in any respect superior to those outstanding shares of any class, or of extending or shortening the term of corporate existence;
- b. In case of sale, lease, exchange, transfer, mortgage, pledge or other disposition of all or substantially all of the corporate property and assets as provided in this Code;
- c. In case of merger or consolidation; and
- d. In case of investment of corporate funds for any purpose other than the primary purpose of the corporation.

Further, under Section 81 of the Revised Corporation Code, the dissenting stockholder who votes against a proposed corporate action may exercise the right of appraisal by making a written demand on the corporation for the payment of the fair value of shares held within thirty (30) days from the date on which the vote was taken. Provided that failure to make the demand within such period shall be deemed a waiver of the appraisal right. If the proposed corporate action is implemented, the corporation shall pay the stockholder, upon surrender of the certificate of stock representing the stockholders' shares, the fair value thereof as of the day before the vote was taken, excluding any appreciation or depreciation in anticipation of such corporate action.

If, within sixty (60) days from the approval of the corporate action by the stockholders, the withdrawing stockholder and the corporation cannot agree on the fair value of the shares, it shall be determined and appraised by three (3) disinterested persons one of whom shall be named by the stockholder, another by the corporation, and the third by the two (2) appraisers thus chosen. The findings of the majority of the appraisers shall be final and their award shall be paid the corporation within thirty (30) days after such award is made; Provided, That no payment shall be made to any dissenting stockholder unless the corporation has unrestricted retained earnings in its books to covers such payment; Provide, further, That upon payment by

the corporation of the agreed or awarded price, the stockholder shall forthwith transfer the shares to the corporation.

Interest of Certain Persons in or Opposition to Matters to be Acted Upon

No director, officer or nominee for election as director of the Company, or associate of a director, officer, or nominee for election as director has any substantial interest in any matter to be acted upon, other than election to office. No director has informed the Company in writing that he intends to oppose any action to be taken by the Company at the meeting.

B. CONTROL AND COMPENSATION INFORMATION**Voting Securities and Principal Holders Thereof**

(a) Class of Voting Shares as of March 31, 2025:

	Shares Outstanding	No. of Vote Each Share Is Entitled
Common Shares:		
Filipino	168,350	One (1) vote per share
Foreign	250	One (1) vote per share
Total	168,600	

(b) Record Date:

All stockholders of record as of June 13, 2025, are entitled to notice of and to vote at the Annual Stockholders' Meeting.

(c) Manner of voting:

The holders of common stock are entitled to one vote per share, except in connection with the election of directors where only the founders are entitled to vote. The founders are entitled to as many votes as shall equal the number of shares held by such person at the close of business on the record date, multiplied by the number of directors to be elected. A founder may cast all of such votes for a single nominee or may apportion such votes among any two or more nominees. The shares shall be voted/cast via the online tool in the Zoom Webinar. In all matters included in the agenda, except the election of directors, the counting of votes will be done through the regular method.

(d) Security Ownership of Certain Record and Beneficial Owners and Management

(1) Security Ownership of Certain Record and Beneficial Owners (of more than 5%) as of March 31, 2025

The persons known to the registrant to be directly or indirectly the record or beneficial owner of more than 5% of the registrant's voting securities as of March 31, 2025, are as follows:

Title of Class	Name, Address of record owner and Relationship with Issuer	Name of Beneficial Owner and Relationship with Record Owner	Citizenship	No. of Shares Held	Percent
Common Founder	Enriquez, Michael Edward R.	Enriquez, Amado Manuel Jr. C./Father	Filipino	19,920 (common shares) 80 (founder shares)	11.86%
Common Founder	Enriquez, Marilyn R.	Enriquez, Amado Manuel Jr. C./Husband			
Common Founder	Enriquez, Miguel R.	Enriquez, Amado Manuel Jr. C./Father			

(1) Security Ownership of Directors and Management as of March 31, 2025:

Name	Amount and Nature of Beneficial Ownership		Citizenship	No. of Shares	% Ownership
	Direct	Indirect			
BOARD OF DIRECTORS					
Enriquez, Amado Manuel Jr. C.	12,500,000	7,500,000	Filipino	19,920 (common shares) 80 (founder shares)	11.86%
Amante, Jonathan C.	2,490,000	2,510,000	Filipino	4,980 (common shares) 20 (founder shares)	2.97%
Tan, Robert H.	2,490,000	2,510,000	Filipino	4,980 (common shares) 20 (founder shares)	2.97%
Cerna-Lopez, Geanie	4,340,000	3,160,000	Filipino	7,470 (common shares) 30 (founder shares)	4.45%
Samoy, Marietta T.	7,500,000	-	Filipino	7,470 (common shares) 30 (founder shares)	4.45%
Arco, Roy Diamond M.	2,500,000	10	Filipino	2,500 (common shares) 10 (founder shares)	1.49%
Eyas, Aejeleth B.	2,500,000	-	Filipino	2,490 (common shares) 10 (founder shares)	1.48%
Ramiro, Ronald	2,500,000	2,500,000	Filipino	4,980 (common shares) 20 (founder shares)	2.97%
De Leon, Roberto	2,500,000	2,500,000	Filipino	4,980 (common shares) 20 (founder shares)	2.97%
Uy, Corazon D.	2,500,000	-	Filipino	2,490 (common shares) 10 (founder shares)	1.48%
Nuico, Glenda N.	2,490,000	2,510,000	Filipino	4,980 (common shares) 20 (founder shares)	2.97%
De La Rosa, Carlos	2,500,000	2,500,000	Filipino	4,980 (common shares) 20 (founder shares)	2.97%
Regalado, Rolando	2,500,000	-	Filipino	2,490 (common shares) 10 (founder shares)	1.48%
Orillaza, Generoso	2,500,000	2,500,000	Filipino	4,980 (common shares) 20 (founder shares)	2.97%
Zozobrado, Evangeline	2,500,000	-	Filipino	2,490 (common shares) 10 (founder shares)	1.48%

Name	Amount and Nature of Beneficial Ownership		Citizenship	No. of Shares	% Ownership
	Direct	Indirect			
EXECUTIVE OFFICERS					
Enriquez, Amado Manuel Jr. C. /Chairman	12,500,000	7,500,000	Filipino	19,920 (common shares) 80 (founder shares)	11.93%
Tan, Robert H. /President	2,490,000	2,510,000	Filipino	4,980 (common shares) 20 (founder shares)	2.97%
Cerna-Lopez, Geanie /Vice Chairperson	4,340,000	3,160,000	Filipino	7,470 (common shares) 30 (founder shares)	4.45%
Samoy, Marietta T. / Vice President	7,500,000	—	Filipino	7,470 (common shares) 30 (founder shares)	4.49%
Eyas, Aejeleth /Corporate Secretary	2,500,000	-	Filipino	2,490 (common shares) 10 (founder shares)	1.48%
Arco, Roy Diamond M. /Treasurer	2,500,000	10	Filipino	2,500 (common shares) 10 (founder shares)	1.49%
Ramiro, Roland / Asst. Corporate Secretary	2,500,000	2,500,000	Filipino	4,980 (common shares) 20 (founder shares)	2.97%
Enriquez, Michael Edward /Asst. Treasurer	2,500,000		Filipino	2,490 (common shares) 10 (founder shares)	1.48%

(3) There are no voting trust holders of 5% or more.

(4) The Company is not aware of any voting trust agreement/s or similar agreement/s which may result in a change in control of the Company.

(e) No change in control of the registrant has occurred since the beginning of its last fiscal year.

Directors and Executive Officers

(a) Directors/Nominees and Executive Officers

There are fifteen (15) members of the Board, three (3) of whom are independent directors. The term of office of each member is one (1) year; they are elected at the annual stockholders' meeting to hold office until the next succeeding annual stockholders' meeting and until his/her successor is elected and qualified. A director who is elected to fill any vacancy holds office only for the unexpired term of his predecessor. The current members of the Board of Directors are the following:

1. Amado Manuel C. Enriquez Jr.
2. Marietta Samoy
3. Geanie Cerna-Lopez
4. Roberto De Leon
5. Carlos De La Rosa
6. Ronald Ramiro

7. Robert H. Tan
8. Jonathan C. Amante
9. Roy Diamond M. Arco
10. Glenda Nuico
11. Aejeleth B. Eyas
12. Corazon Uy
13. Rolando Regalado - Independent Director
14. Evangeline Zozobrado – Independent Director
15. Generoso Orillaza – Independent Director

The nominees for this year are the following:

1. Amado Manuel C. Enriquez Jr.
2. Marietta Samoy
3. Geanie Cerna-Lopez
4. Robert H. Tan
5. Michael Edward Enriquez
6. Ronald Ramiro
7. Esmeralda De La Rosa
8. Roy Diamond M. Arco
9. Revey Nuico
10. Franciene Vasquez
11. Brenda Diputado
12. Idelle Marie Yurong
13. Concepcion Rosario - Independent Director
14. Eulenia Nolasco – Independent Director
15. Generoso Orillaza – Independent Director

Please refer to attached Annex “A” for the summary of qualifications of the current Directors, Officers and Nominees.

The Company has complied with the guidelines on the nomination and election of independent directors as set forth in Rule 38 of the Amended Implementing Rules and Regulations of the Securities Regulation Code. The nominated independent directors are as follows: Concepcion Rosario, Eulenia Nolasco, and Generoso Orillaza, were nominated by Silahis Rosario, Aejeleth Eyas and Robert H. Tan, respectively. The nominees are not related to their respective nominating stockholder and were pre-screened by the Nominations Committee, composed of Robert H. Tan (Chairman), Generoso Orillaza (Independent Director), Geanie Cerna-Lopez, Glenda Nuico, Corazon Uy, Marilou Buenaventura (non-voting) and Miguel Antonio Enriquez (non-voting).

The Company’s key executive officers as of March 31, 2025, are as follows:

Name	Age	Citizenship	Position
Amado Manuel C. Enriquez Jr.	72	Filipino	Chairman
Geanie Cerna-Lopez	70	Filipino	Vice Chairman
Robert H. Tan	65	Filipino	President
Marietta Samoy	68	Filipino	Vice President
Roy Diamond M. Arco	48	Filipino	Corporate Treasurer
Aejeleth B. Eyas	44	Filipino	Corporate Secretary
Ronald Ramiro	68	Filipino	Assistant Corporate Secretary
Michael Edward R. Enriquez	37	Filipino	Assistant Treasurer

The Officers (per the Company’s By-Laws) are elected/appointed annually by the Board of Directors during its organizational meeting following the annual stockholders’ meeting, each to hold office for one (1) year until the next organizational meeting of the Board in the following year or until a successor shall

have been elected/appointed and shall have qualified. Please refer to attached Annex “A” for the summary of qualifications of the Executive Officers.

Significant Employees

The Corporation relies significantly on the continued collective efforts of its senior executive officers and expects each employee to do his share in achieving the Corporation's goals. All the employees are expected to have significant contribution, based on their respective positions, to the business of the Corporation.

Certain Relationships and Related Transactions

The Company, in the normal course of business, transacts business with individuals which are considered related parties. The following were carried out with related parties as at March 31, 2025 and December 31, 2024:

Category	Advances from shareholders 2024	Amount of Transactions 2025	Advances from shareholders 2025	Terms	Conditions
Advances from shareholders					
Non-interest-Bearing	27,945,354	3,910,000	31,855,354	Non-interest-bearing, to be paid in cash (a)	Unsecured, unguaranteed, not impaired
Interest Bearing	—	—	—	Interest-bearing, to be paid in cash (b)	Unsecured, unguaranteed, not impaired
	27,945,354	3,910,000	31,855,354		

Category	Advances from shareholders 2023	Amount of Transactions 2024	Advances from shareholders 2024	Terms	Conditions
Advances from shareholders					
Non-interest-Bearing	2,384,654	25,560,700	27,945,354	Non-interest-bearing, to be paid in cash (a)	Unsecured, unguaranteed, not impaired
Interest Bearing	—	—	—	Interest-bearing, to be paid in cash (b)	Unsecured, unguaranteed, not impaired
	2,384,654	25,560,700	27,945,354		

(a) Non-interest-bearing Advances from shareholders

In the special meeting of the Board held last May 7, 2017, the directors and shareholders were mandated and empowered to contribute resources and make cash advances to the Company for the development of its medical structures and appurtenances. In view of this, the shareholders advanced the monies in support of the Company's building construction requirements. These advances are non-interest bearing and to be paid subject to availability of funds and/or the Board may decide to convert said advances to equity in the distant future. The Company, however, also reserves the right to defer settlement and prioritize completion of the hospital building.

(b) Interest-bearing Advances from shareholders

On June 3, 2019, the Company acquired an unsecured interest-bearing advance from the shareholders at 12% per annum which was primarily used by the Company to support the working capital requirement during the start of its operation. The Company, however, reserves the right to defer settlement in favor of prioritizing payments relative to hospital construction. Total finance costs on these loans amounted to nil, ₱896,230 and ₱1,402,619 in 2024, 2023 and 2022, respectively.

Family Relationships

Among the directors and officers of Allied Care Experts (ACE) Dumaguete Doctors, Inc., the assistant corporate treasurer, Michael Edward Enriquez, is the son of Dr. Amado Manuel Enriquez, Jr. a member of the Board of Directors. There are no other directors or officers, aside from the aforementioned, who have family relationship.

Involvement in Certain Legal Proceedings

As of April 30, 2025, none of the nominees for election as director, executive officer, underwriter or control person of the registrant has been involved in the following: (1) Bankruptcy; (2) Conviction by final judgment; (3) Being subject to any Order, Judgment or Decree; and (4) Violation of Securities or Commodities Law.

No director has resigned or declined to stand for re-election to the board of directors since the date of the last annual meeting of security holders due to disagreement with the registrant on any matter relating to the registrant's operations, policies, and practices.

There is no action to be taken with respect to: (a) merger or consolidation of the registrant into or with any other person or of any other person into or with the registrant; (b) acquisition by the registrant or any of its security holders of securities of another person; (c) acquisition by the registrant of any other going business or of the assets thereof; (d) sale or transfer of all or any substantial part of the assets of the registrant; and (e) liquidation or dissolution of the registrant.

There is no acquisition or disposition of property.

There is no restatement of Assets, Capital or Surplus Accounts

(b) Compensation of Directors and Executive Officers

SUMMARY COMPENSATION TABLE

(a)	(b)	(c)	(d)	(e)
Name & Principal Position	Year	Salary	Bonus	Other Compensation
A. Amado Manuel C. Enriquez, Jr. Chairman	2024	610,000	- 0 -	- 0 -
B. Robert H. Tan President	2024	911,000	- 0 -	- 0 -
C. Roy Diamond M. Arco Corporate Treasurer	2024	383,000	- 0 -	- 0 -
D. Aejeleth B. Eyas Corporate Secretary	2024	383,000	- 0 -	- 0 -
E. Aggregate For The Above Named CEO & Officers	2025- estimate	2,170,000	- 0 -	- 0 -
	2024	2,287,000	- 0 -	- 0 -
	2023	1,497,500	- 0 -	- 0 -
F. Aggregate For The Officers And Directors As A Group	2025- estimate	4,130,000	- 0 -	- 0 -
	2024	4,177,000	- 0 -	- 0 -
	2023	3,387,500	- 0 -	- 0 -

- a. The directors receive per diem of P10,000.00/board meeting and P5,000.00 per committee meeting during board/committee meetings for each director. On November 30, 2020, the Board approved the compensation for officers, as follows:

Position	Amount
Chairman	90,000
President	90,000
Vice Chairman	80,000
Vice President	80,000
Corporate Treasurer	65,000
Assistant Treasurer	60,000
Corporate Secretary	65,000
Assistant Corporate Secretary	60,000

For the year 2024, the directors received per diem for attendance in board and committee meetings as shown in the table below:

Name of Director	Total Per Diem Received for the Year 2024
Amado Manuel C. Enriquez Jr.	375,000
Marietta Samoy	365,000
Geanie Cerna-Lopez	360,000
Roberto De Leon	120,000
Carlos De La Rosa	40,000
Ronald Ramiro	85,000
Robert H. Tan	375,000
Jonathan C. Amante	235,000
Roy Diamond M. Arco	115,000
Glenda Nuico	117,000
Aejeleth B. Eyas	365,000
Corazon Uy	20,000
Rolando Regalado	40,000
Evangeline Zozobrado	30,000
Generoso Orillaza	40,000

- b. There are no bonuses, profit sharing or other compensation plan, contract or arrangement in which any director, nominee for election as director, or executive officers of the registrant will participate.
- c. The Company has no existing options, warrants or rights to purchase any securities.
- d. The value of the securities is based on the approved issue price thereof as stated in the Registration Statement of the Corporation.

(c) Independent Public Accountants

The Company's external auditor is the auditing firm of Ong, Noceja & Associates, is being recommended by the Board, based on the recommendation of the Audit Committee composed of Evangeline Zozobrado (Chairman/Independent Director), Rolando Regalado (Independent Director), Roy Diamond Arco, Ronald Ramiro, and Carlos De La Rosa, subject to stockholders' approval.

The Audit Committee has the function of assessing the independence and professional qualifications of the external auditor, in compliance with the requirements under applicable law, rules and regulations; reviewing the performance of the external auditors. Prior to the commencement of the audit, the Audit Committee shall discuss, review and recommend with the external auditors the nature, scope and fees of the audit.

Lagrimas N. Ong, is the external auditor of the Company for the most recently completed year 2024. Pursuant to Revised SRC Rule 68 (3) (b) (ix) (re: rotation of external auditors), the Company has not engaged Lagrimas N. Ong for more than seven years. Lagrimas Ong has been the signing partner for the past year only.

Representatives of Lagrimas N. Ong are expected to be present during the annual stockholders' meeting. The representatives will have the opportunity to make statements if they desire to do so and will be available to respond to appropriate questions from the security holders.

During the two (2) most recent fiscal years or any subsequent interim period, the independent auditor has not resigned nor was dismissed nor has declined to stand for reappointment after the completion of the current audit; there were no disagreements with the said independent accountants on any matter of accounting and financial disclosure.

The aggregate annual external audit fees billed for each of the last two (2) fiscal years for the audit of the registrant's annual financial statements or services that are normally provided by the external auditor are as follows:

For the year 2024- ₱201,600.00 (billed and paid in 2025)

For the year 2023- ₱308,000.00 (billed and paid in 2024)

The above audit fees include audit, other assurance and related services by the External Auditor that are reasonably related to the performance of the audit or review of the Company's financial statements (a) P180,000.00 in 2024, and P275,000 in 2023; and (b) All Other P21,600.00 in 2024, and P33,000 in 2023).

Except for the audit of the Company's financial statements, no other professional services are rendered to the Company by the external auditor.

C. OTHER MATTERS

Action with Respect to Reports

The approval of the stockholders on the following will be taken up:

- i. Minutes of the July 2, 2024 Annual Stockholders' Meeting. The Minutes cover the following items:
 - A. Reading and Approval of the Minutes of the Y2023 Annual Stockholders' Meeting
 - B. Audited Financial Report 2023
 - C. President's Report
 - D. Election of the Board of Directors 2024-2025
 - E. Appointment of External Auditor for Y2024

The approval or disapproval of the above Minutes will refer only to the correctness of the Minutes and will not constitute an approval/disapproval of the matters stated in the Minutes.

- ii. Audited Financial Statements for the year ending 31 December 2024.

Other Proposed Actions

1. Ratification of all corporate acts and resolutions during the past year of the Board, Officers and Management. These acts are covered by resolutions duly adopted in the usual course of business such as opening of bank accounts and designation of authorized signatories for various transactions, etc.
2. Election of Directors for Y2025-2024
3. Appointment of External Auditor for fiscal year ending 31 December 2025

Amendment of Charter, By-Laws and other Documents

There is no action to be taken with respect to the Company's charter, bylaws or other documents.

Voting Procedures

Except on the election of directors, an affirmative vote by the stockholders owning at least a majority of the outstanding capital stock shall be sufficient to approve matters requiring stockholder's action. The holder of a majority interest of all outstanding stock of the Company entitled to vote at the meeting, in person or by proxy, shall constitute a quorum for the transaction of business. The holders of common stocks are entitled to one vote per share, except in connection with the election of directors where only the founders are entitled to vote. The founders shall be entitled to as many votes as shall equal the number of shares held by such person at the close of business on the record date, multiplied by the number of directors to be elected. The founder may cast all of such votes for a single nominee or may apportion such votes among any two or more nominees. The shares shall be voted/cast via the online poll thru the Zoom Webinar. Stockholders shall be entitled to vote either in person or by proxy.

Method of Counting Votes

The Corporate Secretary, assisted by the Company's external auditor, will be responsible for counting the votes.

Compliance with Section 49 of the Revised Corporation Code

Voting was done through the online poll that was launched during the annual stockholders meeting. The tabulation of the votes was done by the Board of Canvassers based on the votes received thru the online poll.

The stockholders were given the opportunity to ask their questions through the chatroom during the meeting. There were no questions raised by the stockholders.

The following matters were taken up:

- I. Welcome Message from the Vice Chairman of the Board
- II. Reading and Approval of the Minutes of the Y2023 Annual Stockholders' Meeting
The draft minutes was presented to and was approved unanimously by the stockholders present.
- III. Approval of the Y2023 Audited Financial Statement
The Y2023 audited financial statements was presented to and was approved by the stockholders present.
- IV. President's Report
The president rendered his report to the stockholders on the Company's performance for Y2023.
- V. Ratification of the Acts and Proceedings of the Board of Directors, Officers, and Management of the Corporation
The stockholders ratified the acts and proceedings of the board of directors, officers, and management of the Company, as presented in the list of corporate acts.
- VI. Election of the Board of Directors 2024-2025
The following were elected directors for Y2024-2025. There were only 15 nominees for the 15 board seats to be elected; the votes were tabulated as follows:

Name of Nominee	Number of Votes
1. Enriquez, Amado Manuel Jr C.	150,120
2. Amante, Jonathan C.	150,580
3. Tan, Robert H.	150,500
4. Cerna-Lopez, Geanie	150,000
5. Samoy, Marietta	150,000
6. Eyas, Aejeleth	150,230
7. Ramiro, Ronald	150,000
8. Arco, Roy Diamond	150,540
9. De La Rosa, Carlos	150,000
10. De Leon, Roberto	150,000
11. Nuico, Glenda	150,370
12. Uy, Corazon	150,070
13. Regalado, Rolando – Independent Director	150,080
14. Orillaza, Generoso – Independent Director	150,000
15. Zozobrado, Evangeline – Independent Director	150,000

- VII. Appointment of External Auditor for the year 2024
The stockholders approved the appointment of Ong, Noceja & Associates, as the Company's external auditor for Y2024.

Except for the election of officers, all the matters taken up were approved by the stockholders present during the meeting.

Attached as Annex "D" is the list of the directors, officers and stockholders who attended the meeting. Also attached as Annex "E", is the Attendance Sheet of the Directors for the year 2024.

Except on the election of directors, an affirmative vote by the stockholders owning at least a majority of the outstanding capital stock shall be sufficient to approve matters requiring the stockholder's action. The holder of a majority interest of all outstanding stock of the Company entitled to vote at the meeting, in person or by proxy, shall constitute a quorum for the transaction of business. The holders of common stocks are entitled to one vote per share, but in connection with the cumulative voting feature applicable to the election of directors, each stockholder is entitled to as many votes as shall equal the number of shares held by such person at the close of business on the record date, multiplied by the number of directors to be elected. A stockholder may cast all of such votes for a single nominee or may apportion such votes among any two or more nominees. The shares shall be voted/cast by secret balloting and/or raising of hands. Stockholders shall be entitled to vote either in person or by proxy.

Below is the Board Performance Appraisal Report for the year 2024:

PERFORMANCE ASSESSMENT FOR THE BOARD OF DIRECTORS

(January 1, 2024- December 31, 2024)

Good Corporate Governance Principles and Practices	Rating
1. The Board is composed of competent, hardworking members that foster the long-term success of the corporation and sustain its competitiveness and growth.	5
2. The Board is headed by a competent and qualified chairperson.	5
3. The Board practices diversity which avoids groupthink and ensures that optimal decision-making is achieved.	4
4. The Board members act on a fully-informed basis, in good faith, with due diligence and care, and in the best interest of the company and the shareholders and all other stakeholders	5
5. The Board oversees the development of and approves the company's business and strategy and monitor its implementation, in order to sustain the company's long-term viability and strength	5
6. The Board ensures an effective succession planning program for directors, key officers and Management to ensure the continuous and consistent growth of the company.	5
7. The Board aligns the remuneration of key officers and board members with the long-term interest of the company.	5
8. The Board has adopted a formal nomination and election policy which provides for the procedures on how the Board accepts nominations.	5
9. The Board ensures the integrity of related party transactions and other unusual transactions, particularly those which pass certain threshold materiality. The Board reviews and approves material RPTs to guarantee fairness and transparency of the transactions.	5
10. The Board has an internal control system in place and a mechanism to monitor and manage potential/actual conflicts of interests of board members, management and shareholders.	5
11. Board has organized board committees to support the effective performance of the board functions, particularly, with respect to audit, risk management, compliance and other key corporate governance concerns, such as nomination and remuneration.	5

12. The Board endeavors to exercise an objective and independent judgment on all corporate affairs.	5
13. The Board has at least 2 independent directors, or at least 20% of the members of the Board, whichever is higher.	5
14. The Board regularly carries out evaluations to assess its performance as a body, and whether it possesses the right mix of backgrounds and competencies.	4
15. The Board applies high ethical standards, taking into account the interests of all stakeholders.	5
16. The Board has established corporate disclosure policies and procedures that are practical and in accordance with generally accepted best practices and regulatory expectations.	5

On June 3, 2019, the Company acquired an unsecured interest-bearing advances from the shareholders and/or Board of Directors at 12% per annum which was primarily used by the Company to support the working capital requirement during the start of its operation. The Company, however, reserves the right to defer settlement in favor of prioritizing payments relative to hospital construction.

Except for per diem (P10,000.00/board meeting and P5,000.00 per committee meeting) for each director, there are no bonuses, profit sharing, or other compensation plans, contract, or arrangement in which any director, nominee for election as a director, or executive officer of the registrant will participate. For the year 2024, the following executive officers receive compensation as such officers:

(a)	(b)	(c)	(d)	(e)
Name & Principal Position	Year	Salary	Bonus	Other Compensation
G. Amado Manuel C. Enriquez, Jr. Chairman	2024	610,000	- 0 -	- 0 -
H. Robert H. Tan President	2024	911,000	- 0 -	- 0 -
I. Roy Diamond M. Arco Corporate Treasurer	2024	383,000	- 0 -	- 0 -
J. Aejeleth B. Eyas Corporate Secretary	2024	383,000	- 0 -	- 0 -
K. Aggregate For The Above Named CEO & Officers	2025- estimate	2,170,000	- 0 -	- 0 -
	2024	2,287,000	- 0 -	- 0 -
	2023	1,497,500	- 0 -	- 0 -
L. Aggregate For The Officers And Directors As A Group	2025- estimate	4,130,000	- 0 -	- 0 -
	2024	4,177,000	- 0 -	- 0 -
	2023	3,387,500	- 0 -	- 0 -

For the year 2024, the directors received per diem for attendance in board and committee meetings as shown in the table below:

Name of Director	Total Per Diem Received for the Year 2024
Amado Manuel C. Enriquez Jr.	375,000
Marietta Samoy	365,000
Geanie Cerna-Lopez	360,000
Roberto De Leon	120,000
Carlos De La Rosa	40,000
Ronald Ramiro	85,000
Robert H. Tan	375,000
Jonathan C. Amante	235,000
Roy Diamond M. Arco	115,000
Glenda Nuico	117,000
Aejeleth B. Eyas	365,000
Corazon Uy	20,000
Rolando Regalado	40,000
Evangeline Zozobrado	30,000
Generoso Orillaza	40,000

The directors receive per diem of P10,000.00/board meeting and P5,000.00 per committee meeting during board/committee meetings for each director. On November 30, 2020, the Board approved the compensation for officers, as follows:

Position	Amount
Chairman	90,000
President	90,000
Vice Chairman	80,000
Vice President	80,000
Corporate Treasurer	65,000
Assistant Treasurer	60,000
Corporate Secretary	65,000
Assistant Corporate Secretary	60,000

The Company has put in place, sufficient internal controls and risk management system to ensure the efficient management of the various risks concomitant to our hospital operations.

The Company's external auditor is the auditing firm of Ong, Noceja & Associates.

The aggregate annual external audit fees billed for year 2024 was ₱201,600. The said fees include: (a) audit, other assurance and related services by the External Auditor that are reasonably related to the performance of the audit or review of financial statements (₱180,000.00); and (b) All Other Fees, including estimated out of pocket expenses accrued by the Company as of December 31, 2024 (Php₱21,600.00).

The Company has not yet declared dividends since its incorporation in 2015, considering that it does not have earnings yet. As stated in the Company's By-Laws, dividends shall be declared and paid out of the unrestricted retained earnings which shall be payable in cash, property, or stock to all stockholders on the basis of outstanding stock held by the stockholders as often and at such times as may be decided by the Board of Directors.

The directors have no self-dealing or related party transactions as of December 31, 2024.

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this report is true, complete and correct. This report is signed in the City of Dumaguete on **June 2, 2025**.

ALLIED CARE EXPERTS(ACE) DUMAGUETE DOCTORS INC.

By:



AEJELETH B. EYAS
Corporate Secretary

Upon the written request of the stockholder, the Company undertakes to furnish said stockholder a copy of SEC Form 17-A free of charge, except for exhibits attached thereto which shall be charged at cost. Any written request for a copy of SEC Form 17-A shall be addressed as follows:

Allied Care Experts(ACE) Dumaguete Doctors Inc.
F . Cimafranca St. Daro, Dumaguete City 6200
Attention: The Corporate Secretary

ANNEX “A”

INCUMBENT BOARD OF DIRECTORS/NOMINEES

Hereunder is the complete and updated list of the directors, officers and nominees of the Corporation:

Name	Business and Professional Work Experience
Incumbent Board of Directors	
Enriquez, Amado Manuel Jr. C. 72, Filipino	<p>Chairman – Allied Care Experts (ACE) Dumaguete Doctors Inc. (2015-2023, 2024-present) Director – Allied Care Experts (ACE) Dumaguete Doctors Inc. (2015-present) Founder – Allied Care Experts (ACE) Dumaguete Doctors Inc. (2015)</p> <p>Alaminos Medical Center Foundation (2001-present) Founding Director - Mania</p> <p>Active consultant in Cardiovascular-Thoracic Surgery – St. Luke’s Medical Center, Manila East Medical Center, ACE Medical Center Hospitals.</p> <p>Previous Positions Held: Chairman of the Board – Manila East Medical Center (2007-2008, 2017); Paranaque Doctors Hospital (2012-2017); ACE Medical Center Baypointe, Subic (2007-2011); Unihealth Paranaque Hospital (2014-2017)</p> <p>Founding Chairman – ACE Medical Center Valenzuela, ACE Medical Center Baliwag, ACE Medical Center Pateros, ACE Medical Center Malolos, ACE Medical Center Mandaluyong, ACE Medical Center Palawan, ACE Medical Center Iloilo, ACE Medical Center Tacloban, ACE Dumaguete Doctors, Inc., ACE Dumaguete Doctors, Inc., ACE Medical Center Bacolod, ACE Medical Center General Santos, ACE Medical Center CDO, ACE Medical Center Dipolog, ACE Medical Center Zamboanga, ACE Medical Center Butuan</p>
Amante, Jonathan C. 68, Filipino	<p>President – Allied Care Experts (ACE) Dumaguete Doctors (2015-2023) Director - Allied Care Experts (ACE) Dumaguete Doctors (2015-present) Founder – Allied Care Experts (ACE) Dumaguete Doctors Inc. (2015)</p> <p>Chairman - University Of The Philippines – PGH Review for Philippine College of Physicians Examination (1987)</p> <p>Diplomate And Fellow - Philippine College Of Physician , Philippine Society of Nephrology</p>

Name	Business and Professional Work Experience
	<p>Holy Child Hospital - Head, Dialysis Unit (1988); Chairman, Dept. Of Medicine Silliman Medical Centre - Head, Dialysis Unit (1988); NOPH - Head, Provincial Dialysis Unit</p> <p>Association Of Philippine Medical Colleges Member, Board Of Trustees ; Ace Medical Centre- Bayawan, Inc. - Member, Board Of Directors And Management Consultant (Feb 2016 – up to present)</p> <p>Director - Allied Care Experts (ACE) Dumaguete Doctors (2015-present)</p> <p>Consultant, ACE Dumaguete Doctors and Silliman Medical Center Department of Internal Medicine</p>
<p>Tan, Robert H. 65, Filipino</p>	<p>President – Allied Care Experts (ACE) Dumaguete Doctors Inc., (2023-present) Founder – Allied Care Experts (ACE) Dumaguete Doctors Inc. (2015)</p> <p>Consultant, General Surgeon, Holy Child Hospital (1993-present); Consultant, General Surgeon, ACE Dumaguete Doctors Visiting Consultant, General Surgery Silliman University Medical Centre (1993 - present)</p>
<p>Cerna-Lopez, Geanie 70, Filipino</p>	<p>Founder – Allied Care Experts (ACE) Dumaguete Doctors Inc. (2015)</p> <p>President - Las Pinas City Medical Center, Medical Director- Unihealth Paranaque, Management Consultant - Medical Center Muntinlupa,</p> <p>Past President - Medical Center Muntinlupa (2016), Past Hospital Admin - UniHealth Paranaque Hospital (2016) and Las Pinas City Medical Center(2016); Past president Paranaque Doctors Hospital (2015)</p>
<p>Samoy, Marietta T. 68, Filipino</p>	<p>Corporate Secretary – Allied Care Experts (ACE) Dumaguete Doctors Inc., (2021-2023) Vice President - Allied Care Experts (ACE) Dumaguete Doctors Inc., (2023-present) Founder – Allied Care Experts (ACE) Dumaguete Doctors Inc. (2015)</p> <p>Obstetrics and Gynecology Consultant in Las Pinas, Muntinlupa and Paranaque.</p> <p>Medical Center Muntinlupa Medical Services Head, Las Pinas City Medical Center- Administrator, Uni-Health Paranaque Hospital and Medical center- management consultant. Paranaque Doctors Hospital, Head Ob-Gyne Dept.</p>

Name	Business and Professional Work Experience
	<p>Past President Las Pinas Med Center (2014) , Past president UniHealth Paranaque (2016) , Treasurer- medical center Muntinlupa (2015) , Past Corp Sec Paranaque Doctors Hospital (2013), Medical Director - Paranaque Doctors Hospital (2010-2012).</p> <p>Founder – Las Pinas Medical Center, Paranaque Doctors Hospital, Medical Center Muntinlupa, Metrosouth Medical Center, Unihealth Paranaque Hospital and Medical Center, Diliman Doctors Hospital</p>
De Leon, Roberto M. 73, Filipino	<p>Founder – Allied Care Experts (ACE) Dumaguete Doctors Inc. (2015)</p> <p>Active Consultant – Delos Santos Medical Center, James L. Gordon Memorial Medical Center, Sta. Teresita General Hospital.</p> <p>Chairman, Unihealth-Baypointe Hospital & Medical Center, Inc. (Subic Bay Freeport Zone) 2017</p> <p>President, Unihealth-Valenzuela Hospital & Medical Center 2017</p> <p>Medical Director, YGEIA Medical Center</p> <p>Chairman, Dept. of Surgery, ACE Medical Center Valenzuela; Uni-Health Paranaque Hospital and Medical Center 2017</p>
Arco, Roy Diamond M. 48, Filipino	<p>Treasurer - Allied Care Experts (ACE) Dumaguete Doctors Inc. (2015-2020, 2021-2023,2024-present)</p> <p>Founder – Allied Care Experts (ACE) Dumaguete Doctors Inc. (2015)</p> <p>Consultant, ACE Dumaguete Doctors and Silliman Medical Center</p> <p>Department Chairperson – ACEDDI Hemodialysis Unit</p> <p>Corporate Treasurer - ACEDDI</p> <p>PGI – SUMCFI</p> <p>Residency Training – Perpetual Succor Hospital Cebu City, Internal Medicine</p> <p>Fellowship Training – National Kidney & Transplant Institute, Adult Nephrology</p> <p>Diplomate – Philippine College of Physicians (2009)</p> <p>Diplomate – Philippine Society of Nephrology (2012)</p> <p>Member of Professional Organization: Negros Oriental Medical Society, PCP Negros Oriental & Philippine Society of Nephrology</p>
De la Rosa, Carlos 73, Filipino	<p>Founder – Allied Care Experts (ACE) Dumaguete Doctors Inc. (2015)</p> <p>Retired Banker</p>

Name	Business and Professional Work Experience
Nuico, Glenda 66, Filipino	<p>Founder – Allied Care Experts (ACE) Dumaguete Doctors Inc. (2015)</p> <p>Consultant of ACE Dumaguete Doctors Inc and Silliman University Medical Center</p> <p>Silliman University – BS General Science</p> <p>Cebu Doctors College of Medicine / Silliman University - Doctor of Medicine</p> <p>Cebu Doctors Hospital – Residency Training – Pediatrics</p> <p>Philippine Pediatric Society – Diplomate</p> <p>Philippine Pediatric Society – Fellowship</p> <p>Member of Societies: Philippine Pediatric Society , Negros Oriental Medical Society – Philippine Medical Association</p>
Ramiro, Ronald 67, Filipino	<p>Founder – Allied Care Experts (ACE) Dumaguete Doctors Inc. (2015)</p> <p>Assistant Corporate Secretary - Allied Care Experts (ACE) Dumaguete Doctors Inc. (present)</p> <p>President – ACEMC-Bohol (present)</p> <p>Graduated from CIM in 1981 and finished residency in General surgery as Chief Resident at Cebu Doctors Hospital in 1989</p> <p>Passed only part 1 of the Philippine Board of Surgery in 1993</p>
Uy, Corazon 67, Filipino	<p>Founder – Allied Care Experts (ACE) Dumaguete Doctors Inc. (2015)</p> <p>Consultant at ACE Dumaguete Doctors Inc</p> <p>Silliman University – BS General Science</p> <p>University of the Philippines – Doctor of Medicine</p> <p>Philippine General Hospital – Residency in Obstetrics and Gynecology</p> <p>Philippine Board of Obstetrics and Gynecology – Diplomate</p> <p>Philippine Board of Obstetrics and Gynecology – Fellow</p>
Zozobrado, Evangeline 72, Filipino	<p>Founder – Allied Care Experts (ACE) Dumaguete Doctors Inc. (2015)</p> <p>President – Muntlupa Medical Center (2025-present)</p> <p>Corporate Treasurer – ACE Cebu (2025-present), Salt Lake Medical Center Inc. (2021-present),</p> <p>Corporate Secretary – ACE Tacloban (2025-present), Prime Hospital and Medical Center – Pasig, Inc. (2017-present), Great Valley Medical Center Inc. (2020-present), Visayas Ave. Medical Center (2020-present), North Valley Medical Center Inc., (2021-present)</p> <p>Hospital Administrator – Diliman Doctors Hospital (2017-2018)</p> <p>Las Pinas Medical Center (1999-2024)</p> <p>Silliman University – BS General Science</p>

Name	Business and Professional Work Experience
	Cebu Institute of Medicine – Doctor of Medicine Rizal Medical Center – Residency – Pediatrics Philippine Pediatric Society – Fellow Philippine Pediatric Society - Diplomate
Eyas, Aejeleth B. 44, Filipino	Founder – Allied Care Experts (ACE) Dumaguete Doctors Inc. (2015) Corporate Secretary - Allied Care Experts (ACE) Dumaguete Doctors Inc. (present) Consultant, ACE Dumaguete Doctors and Silliman Medical Center Department of Pediatrics Member, Medical Records and Library Committee, SUMC Foundation Inc. Associate Professor, Silliman University Medical School (2012-2016) Silliman University - BS Med Tech Cebu Institute of Medicine- Doctor of Medicine Silliman Medical Center Foundation Inc- Pediatrics Diplomate, Philippine Pediatric Society
Regalado, Rolando 71, Filipino	Consultant of Silliman University Medical Center. Doctor of Medicine – UERMMMC College of Medicine PGI – Silliman University Medical Center Residency Training – UERM Memorial Hospital Fellowship – Philippine College of Surgery Diplomate – Philippine Board of Ophtalmology MAHAD – Cebu Doctors Hospital Founding Doctor of ACEDDI Member of Societies: Philippine Medical Association, Philippine College of Surgery, Philippine Society of Ophtalmology, Rotary Club Dgte Ctiy, Negros Oriental Medical Society.
Orillaza, Generoso 68, Filipino	Director – Paranaque Doctors Hospital (2007 – present); ACE Baypointe Hospital & Medical Center (2010- present); ACE Baliwag (2012-2014) Head, Engineering and Maintenance Service- ACE Valenzuela (2011-2014); ACE Baypointe Hospital & Medical Center (2010-present); ACE Baliwag (2012-2014); Unihealth Paranaque Hospital and Medical Center 2014-2014); ACE Pateros (2013-2015); ACE QC (2013-present); Chairman of Construction Committee (2008 – present) – ACE Iloilo; ACE Gensan; ACE Cebu; ACE Tacloban; ACE Butuan
Nominees for Election as Members of the Board of Directors	
Amado Manuel C. Enriquez Jr.	<i>Please see foregoing director's profile</i>
Marietta Samoy	<i>Please see foregoing director's profile</i>
Geanie Cerna-Lopez	<i>Please see foregoing director's profile</i>
Robert H. Tan	<i>Please see foregoing director's profile</i>

Name	Business and Professional Work Experience
Amado Manuel C. Enriquez Jr.	<i>Please see foregoing director's profile</i>
Roy Diamond M. Arco	<i>Please see foregoing director's profile</i>
De la Rosa, Esmeralda 69, Filipino	<p>Founder - Allied Care Experts (ACE) Dumaguete Doctors Inc. (2015)</p> <p>College of Medicine – University of Santo Tomas 1980 PGI – Manila Doctors Hospital 1981 Residency – Internal Medicine, East Avenue Medical Center 1983-1987</p>
Diputado, Brenda 69, Filipino	<p>Founder - Allied Care Experts (ACE) Dumaguete Doctors Inc. (2015)</p> <p>Consultant of ACE Dumaguete Doctors Inc. College of Medicine - West Visayas State College PGI - UP-PGH 1981 Residency - UP-PGH – Pediatrics 1983-1985 ; Neurology 1989-1992</p>
Nuico, Revey 69, Filipino	<p>Founder - Allied Care Experts (ACE) Dumaguete Doctors Inc. (2015)</p> <p>Consultant of ACE Dumaguete Doctors Inc. College of Medicine – MHAM College of Medicine PGI – Siliman University Medical Center, 1983 Residency – General Surgery, Cebu City Medical Center, 1988</p>
Yurong, Idelle Marie 57, Filipino	<p>Founder - Allied Care Experts (ACE) Dumaguete Doctors Inc. (2015)</p> <p>Consultant of ACE Dumaguete Doctors Inc. College of Medicine – Cebu Doctor's College of Medicine PGI – Siliman University Medical Center 1993 Residency – Pediatrics, Chong Hua Hospital 2000</p>
Vasquez, Franciene 50, Filipino	<p>Founder - Allied Care Experts (ACE) Dumaguete Doctors Inc. (2015)</p> <p>Consultant, ACE Dumaguete Doctors and Silliman Medical Center PGI - SUMCFI Residency Training – Philippine General Hospital, OB-GYN Ultrasound and Velez General Hospital, OB-GYN Fellowship – Philippine Obstetric & Gyne Society Diplomate – Philippine Board of Obstetric & Gyne Society</p>
Enriquez, Michael Edward 37, Filipino	<p>College of Medicine – University of Santo Tomas 2017 Affiliated with ACE Group of Hospitals</p>

Name	Business and Professional Work Experience
	Outstanding inter in Emergency Medicine by the Philippine General Hospital 2018
Nolasco, Eulenia 73, Filipino	Consultant, Asian Hospital and Medical Center, Manila Doctors Medical Center President, Philippine Society of Gastroenterology President, Philippine Society of Digestive Endoscopy Head, Gastrointestinal Center, UP-PGH Medical Center Head, Gastrointestinal Section, East Ave. Medical Center Chairman, Dept. of Medicine, UPHRMC, Las Pinas City Food and Drug Administration Consultant and Drug Reviewer Member of Editorial Board, World Journal of Gastroenterology
Rosario, Concepcion 60, Filipino	Siliman University – BS Medical Technology Gullas College of Medicine – Doctor of Medicine PGI – Siliman University Medical Center Philippine General Hospital – Residency in Obstetrics and Gynecology Philippine Board of Obstetrics and Gynecology – Diplomate Philippine Board of Obstetrics and Gynecology – Fellow
Orillaza, Generoso	<i>Please see foregoing director's profile</i>

ANNEX “B”

MANAGEMENT REPORT

A. Independent Auditor

During the two most recent fiscal years or any subsequent interim period, the Company’s independent accountant, Lagrimas N. Ong has not resigned, nor was dismissed or otherwise ceased performing services for the Company; there were no disagreements with the said independent accountant on any matter of accounting and financial disclosure.

B. Description of Business

Allied Care Experts (ACE) Dumaguete Doctors Inc. (the “Company”) was incorporated as a domestic corporation under Philippine laws and was duly registered with the Securities and Exchange Commission (SEC) under SEC Registration No. CS201506626 on April 1, 2015.

The Company’s primary purpose is to establish, maintain, operate, own and manage hospitals, medical and related healthcare facilities and businesses such as but without restriction to clinical laboratories, diagnostic centers, ambulatory clinic, condo-hospital, scientific research institutions and other allied undertakings and services which shall provide medical, surgical, nursing, therapeutic, paramedic or similar care, provided that purely professional medical or surgical services shall be performed by duly qualified and licensed physicians or surgeons who may or may not be connected with the hospitals and whose services shall be freely and individually contracted by the patients.

The principal office of the Company is located at DML Building, North Road, Dumaguete City. The hospital construction site is located at Cimafranca St., Daro, Dumaguete City, Negros Oriental.

On February 19, 2019, the Company’s registration was approved under BOI Certificate of Registration No. 2019-034. Thus, the Company is now eligible to enjoy certain grants, particularly, but not limited to – Income Tax Holiday—for a period of 4 years starting from November 2018 or actual start of commercial operations, whichever is earlier (the availment of which shall not be earlier than the date of registration).

The Company was likewise able to secure its license to operate from the Department of Health as a Level II Hospital on June 25, 2019.

Competition

The Company’s principal competitors are the following:

HOSPITAL	LOCATION	BED CAPACITY	CATEGORY	LEVEL CLASSIFICATION
Holy Child Hospital	Bishop Epifanio Surban Street, Dumaguete City	200	Private	Level I
Silliman Medical Center Foundation Inc.	Hibbard Ave, Dumaguete City	300	Private	Level III
Negros Oriental Provincial Hospital	National Highway, Dumaguete City	200	Public	Level I
Negros Polymedic Hospital	Tubtubon, National Highway, Sibulan	100	Private	Level II

The patients will opt to be serviced by ACE Dumaguete Doctors considering its accessibility especially in emergency cases. The Company's good location, quality of the facilities and its competent medical staff will be the hospital's edge over its competitors.

Suppliers

The Company has no existing supply contracts with the principal suppliers. The Company has a broad base of suppliers. The Company is not dependent on one or a limited number of suppliers.

Customers

The Company is not dependent upon a single customer or a few customers due to the nature of the industry.

Government Regulations

Required permits were secured by the Company from the Department of Health (DOH), Food and Drug Administration (FDA) and Philippine Drug Enforcement Agency (PDEA) as part of the normal course of the hospital operations.

The Company has secured the required permits and clearances from the Department of Environment and Natural Resources (DENR) to be able to operate its hospital facility. Implementation of the environmental laws cost ACE-Dumaguete Doctors around P100,000 annually.

The Company is not involved in any legal proceedings.

Employees

Total number of full-time employees as of March 31, 2025, is 458. The breakdown is as follows:

	CBA	Non-CBA	Total
Rank and File	337	83	420
Supervisors	–	26	26
Managers and Top Management	–	12	12
Total	337	121	458

Apart from their regular compensation, the employees are entitled to hospital management discounts as follows:

Services	Regular Employee Discounts
Pharmacy	10%
OR Set	10% (OR Materials)
Laboratory	25%
EEG/ECG/2D Echo/Treadmill	25%
Professional fees	25%
Radiology	25% (Contrast not included)
Physical Therapy	25% (For 10 sessions)
ER Fee	50%
OR Fee	50%
DR Fee	50%
Room Accommodation	50% (45 days only)

Discounts for hospital staff employees and rank and file employees should not exceed ₱75,000 per year while discounts for head nurses, supervisors and department chiefs should not exceed ₱175,000 per year.

The Company does not expect to hire additional employees in the next 12 months.

C. Securities of the Registrant

Market Price, Dividend and Related Stockholder Matters

The securities of Allied Care Experts (ACE) Dumaguete Doctors Inc. are not listed in any stock exchange. Its securities are marketed through its organic salaried employees who serve as salesmen. The high and low sales prices by quarter for the last two (2) years are as follows:

	1st Quarter		2nd Quarter		3rd Quarter		4th Quarter		1st Quarter
Market Price	2023	2024	2023	2024	2023	2024	2023	2024	2025
High	250,000	250,000	250,000	250,000	250,000	250,000	250,000	250,000	250,000
Low	250,000	250,000	250,000	250,000	250,000	250,000	250,000	250,000	250,000

The price as of March 31, 2025 (latest practicable trading date) is P250,000.

There are no debt securities, stock options, securities subject to redemption or call, or warrants to be registered or issued.

There are no securities to be modified or exchanged.

There are no recent sales of unregistered or exempt securities including recent issuance of securities constituting an exempt transaction.

There are approximately 1,818 holders of common and founders shares of the Company as of March 31, 2025. Trading of Company's shares is sporadic.

Please refer to Annex "C" for the list of top 20 stockholders as of March 31, 2025.

No dividends were declared in 2024, 2023 and 2022.

There are no restrictions that limit the payment of dividends on Common Shares.

D. Management's Discussion and Analysis or Plan of Operation

For the First Quarter of 2025

For the three months ended March 31, 2025, the Company's operation has generated net revenue of ₱181.4 million.

	For the three months ended March 31				
	2025	% to Sales	2024	% to Sales	% Change 2025 v 2024
Total Revenue, net	181,410,211	100%	176,951,355	100%	3%
Total Cost of Sales	123,621,871	68%	130,481,297	74%	-5%
Gross Income	57,788,340	32%	46,470,058	26%	24%
Total Gen & Ad Expense	43,930,019	24%	27,202,160	15%	61%
Operating income	13,858,321	8%	19,267,898	11%	-28%
Other charges	3,596,173	2%	6,632,661	4%	-46%
Net Income	10,262,148	6%	12,635,237	7%	-19%

Revenue in 2025 has significantly increased by 3% or ₱4.5 million due to increase in occupancy rate and out-patient census. Direct costs decrease to ₱123.6 million in 2024 from ₱130.5 million in 2025 or a 5% decrease due to the decrease in depreciation and cost of laboratory reagents. Direct costs includes depreciation; cost

of medicines, medical supplies and laboratory reagents; professional fee of resident and junior consultants; salaries and wages of medical staff; and allocated utilities expense.

The Company's operating expenses pertain mainly to salaries and other benefits of administrative employees, allocated depreciation expense, utilities expense, repairs and maintenance, supplies and consumables, and taxes and licenses which represent 80% of the Company's total operating expenses. The total operating expenses has increased by 61% or ₱16.7 million in 2025 as compared to 2024. This is due to the increase in the repairs and maintenance cost of the medical equipment of the Company.

Other charges include other income, interest income and income tax expense for the period.

Financial Position (1st Q 2025)

The following table shows the financial position of the Company as at March 31, 2025 and December 31, 2024:

	March 31, 2025	% to Total Assets	December 31, 2024	% to Total Assets	% Change
Current assets	189,485,070	21%	178,383,714	21%	6%
Noncurrent assets	692,158,194	79%	684,559,217	79%	1%
Total assets	881,643,264	100%	862,942,931	100%	2%
Current liabilities	274,919,084	31%	246,390,899	29%	12%
Noncurrent liabilities	33,107,877	4%	53,197,877	6%	-38%
Total Liabilities	308,026,961	35%	299,588,776	35%	3%
Total Equity	573,616,303	65%	563,354,155	65%	2%
Total liabilities and equity	881,643,264	100%	862,942,931	100%	2%

Balance Sheet Items – 1st Q 2025 compared to 2024

Total current assets increased by 6% or ₱11.1 million in the 1st quarter of 2025 as compared to 2024. The increase in current assets is due to increase in cash and inventories amounting to ₱8.7 million and ₱3.5 million, respectively. The Company has total assets of ₱881.6 million as of March 31, 2025 of which ₱645.3 million or 73% is comprised of the Company's land, building, medical equipment and other properties and equipment.

The liabilities of the Company are mainly consisting of trade payable to suppliers, medical practitioners and related parties, and loans payable to the Land bank of the Philippines totaling ₱149.5 million as of March 31, 2025. Total current liabilities have increased by 12% or ₱28.5 million in 2025 as compared in 2024 due to the increase in payables to suppliers for acquisition of new equipment.

Material Variances Affecting the Statements of Financial Position

Statement of financial position accounts as of March 31, 2025 with variances of plus or minus 5 percent against December 31, 2024 balance are discussed, as follows:

Current assets

1. Cash - The increase in cash is due to increase in cash generated from operating activities. The Company has cash generated from operating activities amounting to ₱65.1 million. This was offset by the increase in loan and interest payments. Total payments amounted to ₱33.7 million in the 1st quarter of 2025 and ₱137.1 million in 2024.
2. Inventories – The increase in inventories is due to increased stocks for the Pharmacy and Laboratory Department due to the increased sales and procedures done. Inventories has increased by 11% or ₱3.5 million in the 1st quarter of 2025.

3. Prepayments and other current assets – The decrease is due to the utilization of creditable withholding tax amounting to ₱2.4 million.

Noncurrent assets

1. Advances to suppliers – Advances to suppliers has increased by 10% or ₱0.8 million due to the deposits made for the purchase of goods and/or services that has not been delivered yet..
2. Intangible assets – Decrease in intangible asset is due to amortization for the year amounting to ₱0.2 million.

Current and Noncurrent Liabilities

1. Trade payable – In 2025, the Company has increased its trade and other payables by 38% or ₱34.8 million due to acquisition of equipment paid through installment. The Company has acquired a new ultrasound machine, 2D echo machine and a video endoscopy system in the 1st quarter of 2025.
2. Advances from shareholders – The increase is due to receipts made throughout the year. Total payments for the year was ₱3.9 million.

For the Full Fiscal Years

Financial Performance (2024)

The following table shows the financial highlights of the Company for the years then ended December 31, 2024 and 2023:

	2024	% to Sales	2023	% to Sales	% Change 2024 v 2023
Total Revenue, net	₱613,058,922	100%	₱605,497,294	100%	1%
Total Cost of Sales	(417,694,316)	68%	(446,741,620)	74%	-7%
Gross Income	195,364,606	32%	158,755,674	26%	23%
Total Gen & Ad Expense	(153,663,061)	25%	(112,759,792)	19%	36%
Operating income	41,701,545	7%	45,995,882	8%	-9%
Other charges	(13,850,719)	-2%	(24,131,611)	-4%	-43%
Net Income	₱27,850,826	5%	₱21,864,271	4%	27%

The Company started its hospital out-patient department operations last March 2019. Out-patient operations include laboratory and radiology procedures, ECG, EEG, 2D Echo, Bone Densitometry and Doctor's clinic consultations. On July 2019, the Company started operating in-patient services. The Company has a 100-bed capacity.

Revenue in 2024 has increased by 1% or ₱7.6 million due to increase in inpatient occupancy rate and OPD census. Cost of sales has decreased to ₱417.69 million in 2024 from ₱446.7 million in 2023 or a 7% decrease. Cost of sales includes depreciation; cost of medicines, medical supplies and laboratory reagents; professional fees, salaries and wages and utilities expense.

The Company's operating expenses pertain mainly to salaries and wages of administrative employees, repairs and maintenance, allocated depreciation expense, supplies and consumable, and bad debt expense which represent 68% of the Company's total operating expenses. The total operating expenses increased by 36% or ₱40.9 million in 2024.

In 2024, the Company has generated net income of ₱27.9 million.

Financial Position (2024)

The following table shows the financial position of the Company as at December 31, 2024 and 2023:

	December 31, 2024	% to Total Assets	December 31, 2023	% to Total Assets	% Change
Current assets	178,383,714	21%	193,914,894	22%	-8%
Noncurrent assets	684,559,217	79%	704,192,114	78%	-3%
Total assets	862,942,931	100%	898,107,008	100%	-4%
Current liabilities	246,390,899	29%	251,779,826	28%	-2%
Noncurrent liabilities	53,197,877	6%	141,134,654	16%	-62%
Total Liabilities	299,588,776	35%	392,914,480	44%	-24%
Total Equity	563,354,155	65%	505,192,528	56%	12%
Total liabilities and equity	862,942,931	100%	898,107,008	100%	-4%

Balance Sheet Items - 2024 compared to 2023

Total current assets decreased by 8% or ₱15.5 million in 2024 as compared to 2023. The decrease in current assets is due to decrease in other current assets amounting to ₱42.2 million. The Company has total assets of ₱862.9 million as of December 31, 2024 of which ₱636.1 million or 74% is comprised of the Company's land, building, medical equipment and other properties and equipment.

The liabilities of the Company is mainly consist of trade payable to suppliers, medical practitioners and related parties, and loans payable to the Land bank of the Philippines totaling ₱179.8 million as of December 31, 2024. Total current liabilities have decreased by 24% or ₱93.3 million in 2024 as compared in 2023 due to the principal payment of the bank loans.

Material Variances Affecting the Statements of Financial Position

Statement of financial position accounts as of December 31, 2024 with variances of plus or minus 5 percent against December 31, 2023 balance are discussed, as follows:

Current assets

4. Cash - The increase in cash is due to increase in cash generated from operating activities. The Company has an increase of ₱31.6 million. This was offset by the increase in loan payments. Total payments amounted to ₱122.0 million in 2024 and ₱114.8 million in 2023.
5. Trade Receivable – The increase in trade receivable of 8% is due to the increase in receivable from HMO, Corporate and GLs. In 2024, receivable from HMO, Corporate and GLs increased from ₱20.3 million to ₱37.6 million. This is due to the increased number of patients availing of financial assistance from government agencies.
6. Prepayments and other current assets – The decrease is due to the reclassification of Input VAT to other accounts.

Noncurrent assets

3. Advances to suppliers – The decrease on the account can be attributed to the delivery of goods and/or services.
4. Property and equipment – The decrease is mainly due to the depreciation of the Company's property and equipment totaling to ₱72.4 million.
5. Intangible assets – Increase in intangible asset is due to additions made during the year totaling to ₱3.7 million.

Current and Noncurrent Liabilities

3. Notes payable – In 2024, the Company has paid a total of ₱122.0 million to its long-term notes payable which caused the decrease in total current and noncurrent notes payable.

4. Advances from shareholders – The increase is due to receipts made throughout the year. Total payments for the year was ₱25.6 million.

Financial Performance (2023)

The following table shows the financial highlights of the Company for the years then ended December 31, 2023 and 2022:

	2023	% to Sales	2022	% to Sales	% Change 2023 v 2022
Total Revenue, net	₱605,497,294	100%	₱515,812,320	100%	17%
Total Cost of Sales	(446,741,620)	74%	(384,860,553)	75%	16%
Gross Income	158,755,674	26%	130,951,767	25%	21%
Total Gen & Ad Expense	(112,759,792)	19%	(77,343,951)	15%	46%
Operating income	45,995,882	8%	53,607,816	10%	-14%
Other charges	(24,131,611)	-4%	(28,676,647)	-6%	-16%
Net Income	₱21,864,271	4%	₱24,931,169	5%	-12%

The Company started its hospital out-patient department operations last March 2019. Out-patient operations include laboratory and radiology procedures, ECG, EEG, 2D Echo, Bone Densitometry and Doctor's clinic consultations. On July 2019, the Company started operating in-patient services. The Company has a 100-bed capacity.

Revenue in 2023 has increased by 17% or ₱89.7 million due to increase in inpatient occupancy rate and OPD census. Cost of sales has increased to ₱446.7 million in 2023 from ₱384.9 million in 2022 or a 16% increase. Cost of sales includes depreciation; cost of medicines, medical supplies and laboratory reagents; professional fees, salaries and wages and utilities expense.

The Company's operating expenses pertain mainly to bad debts expense, salaries and wages of administrative employees, allocated depreciation expense, repairs and maintenance, supplies and consumable, and utilities expense which represent 73% of the Company's total operating expenses. The total operating expenses increased by 46% or ₱35.4 million in 2023.

In 2023, the Company has generated net income of ₱21.8 million.

Financial Position (2023)

The following table shows the financial position of the Company as at December 31, 2023 and 2022:

	December 31, 2023	% to Total Assets	December 31, 2022	% to Total Assets	% Change
Current assets	₱193,914,894	22%	₱228,812,448	23%	-15%
Noncurrent assets	704,192,114	78%	760,738,381	77%	-7%
Total assets	898,107,008	100%	989,550,829	100%	-9%
Current liabilities	251,779,826	28%	245,009,585	25%	3%
Noncurrent liabilities	141,134,654	16%	274,462,987	28%	-49%
Total Liabilities	392,914,480	44%	519,472,572	52%	-24%
Total Equity	505,192,528	56%	470,078,257	48%	7%
Total liabilities and equity	898,107,008	100%	989,550,829	100%	-9%

Balance Sheet Items - 2023 compared to 2022

Total current assets decreased by 15% or ₱34.9 million in 2023 as compared to 2022. The increase in current assets is due to decrease in cash amounting to ₱32.7 million. The Company has total assets of ₱898.1 million as of December 31, 2023 of which ₱685.7 million or 76% is comprised of the Company's land, building, medical equipment and other properties and equipment.

The liabilities of the Company is mainly consist of trade payable to suppliers, medical practitioners and related parties, and loans payable to the Land bank of the Philippines totaling ₱301.8 million as of December 31, 2023. Total current liabilities have increased by 3% or ₱6.8 million in 2023 as compared in 2022.

Material Variances Affecting the Statements of Financial Position

Statement of financial position accounts as of December 31, 2023 with variances of plus or minus 5 percent against December 31, 2022 balance are discussed, as follows:

Current assets

7. Cash - The decrease in cash is due to principal payments of the Company's long-term loans. Principal payments totaled to ₱114,750,000 for the year. This was slightly offset by the increase in revenue and collection throughout the year.
8. Trade Receivable – The decrease in trade receivable of 19% is due to the receivable written off during the year. The Company has also provided an allowance for doubtful accounts amounting to ₱9.0 million.
9. Prepayments and other current assets – The increase is due to the increase in Input VAT from purchases of supplies and consumable. Most of the Company's services are VAT-exempt, thus, Input VAT has not been applied.

Noncurrent assets

6. Advances to suppliers – The decrease on the account can be attributed to the delivery of goods and/or services.
7. Property and equipment – The decrease is mainly due to the depreciation of the Company's property and equipment totaling to ₱78.4 million.
8. Intangible assets – Increase in intangible asset is due to additions made during the year totaling to ₱0.3 million.

Current and Noncurrent Liabilities

5. Notes payable – In 2023, the Company has paid a total of ₱114.8 million to its long-term notes payable which caused the decrease in total current and noncurrent notes payable.
6. Advances from shareholders – The decrease is due to payments made throughout the year. Total payments for the year was ₱19.3 million.

Key Performance Indicators

	Mar. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
CURRENT RATIO = Current assets / Current liabilities	0.69	0.72	0.77
Remarks: The current ratio measures a company's ability to pay short-term obligations or those due within one year. It tells investors and analysts how a company can maximize the current assets on its balance sheet to satisfy its current debt and other payables. Current ratio in 2025 and 2024 decreased as net result of the decrease of other current assets and increase in trade and other payables.			
DEBT TO EQUITY RATIO = Debt / Equity	0.54	0.53	0.78
Remarks: Debt to equity ratio shows the proportions of equity and debt a company is using to finance its assets and it signals the extent to which shareholder's equity can fulfill obligations to creditors. Debt to equity in 2025 and 2024 decreased as a net effect of the loan payments during the year and decrease in the deficit of the Company.			
DEBT TO TOTAL ASSET RATIO = Debt / Asset	0.35	0.35	0.44
Remarks: Debt to total asset ratio is an indicator of a company's financial leverage. It is the percentage of a company's total assets that were financed by creditors. Debt to total asset in 2025 remains the same due to the net effect of decrease in bank loans due to repayment and increase in equity due to profit for the period. Debt to total asset ratio in 2024 decreased as result of principal payments during the year totaling to P122 million.			
ASSET TO EQUITY RATIO = Assets / Equity	1.54	1.53	1.78
Remarks: Asset to equity ratio shows the relationship of the total assets of the Company to the portion owned by shareholders. This ratio is an indicator of the company's leverage (debt) used to finance the firm. Asset to equity ratio in 2024 decreased due to the significant decrease in deficit, and increase in share capital and share premium. No significant change in 2025.			
PROFIT MARGIN = Net Income (Loss) / Net Revenue	0.06	0.05	0.04
Remarks: Profit margin is a measure of the Company's income (loss) relative to its revenue. It represents what percentage of revenue has turned into income or loss. Profit margin in 2025 slightly higher due to the Company's decrease in direct costs.			

There were no material events that would trigger direct or indirect contingent financial obligation that would materially affect the company's operation, including any default or acceleration of obligation.

The Company did not enter into any material off-balance sheet transactions, arrangements, obligations (including contingent obligations), and other relationships with unconsolidated entities or other persons during the period.

There were no any known trends or any known demands, commitments, events or uncertainties that would result in or that were reasonably likely to result in the Company's liquidity increase or decreasing in any material way.

The Company continues to spend for regular capital expenditures during the quarter as disclosed in Note 10 of the unaudited interim financial statements.

There were no known trends, events or uncertainties that have had or that are reasonably expected to have a material favorable or unfavorable impact on net sales or revenues or income from continuing operations.

There were no significant elements of income or loss that did not arise from the Company's continuing operations.

There were no seasonal aspects that had any material effect on the financial condition or results of operations of the Company.

There were no material events subsequent to the end of the interim period that have not been reflected in the financial adjustments of the interim period.

The Company is not a party to any lawsuit or claims arising from the ordinary course of business

E. Certain Relationships and Related Transactions

- 1) During the last two (2) years, no director of the Company has received or become entitled to receive any benefit by reason of any contract with the Company, a related corporation, a firm of which the director is a member or a company of which a director has a substantial financial interest.

There are no transactions in the last two (2) years or proposed transactions to which the Company was or is to be a party, in which any of the following persons had or is to have a direct or indirect material interest:

- i. Any director or executive officer of the Corporation;
- ii. Any nominee for election as a director;
- iii. Any security holders;
- iv. Any member of the immediate family of the preceding persons.

The Company's related parties include its affiliates and shareholders, the Company's key management personnel and others as described below.

A summary of the transactions and account balances with related parties follows:

The Company, in the normal course of business, transacts business with individuals which are considered related parties. The following were carried out with related parties as at March 31, 2025 and December 31, 2024:

Category	Advances from shareholders 2024	Amount of Transactions 2025	Advances from shareholders 2025	Terms	Conditions
Advances from shareholders					
Non-interest-Bearing	27,945,354	3,910,000	31,855,354	Non-interest-bearing, to be paid in cash (a)	Unsecured, unguaranteed, not impaired
Interest Bearing	—	—	—	Interest-bearing, to be paid in cash (b)	Unsecured, unguaranteed, not impaired
	27,945,354	3,910,000	31,855,354		

Category	Advances from shareholders 2023	Amount of Transactions 2024	Advances from shareholders 2024	Terms	Conditions
Advances from shareholders					
Non-interest- Bearing	2,384,654	25,560,700	27,945,354	Non-interest- bearing, to be paid in cash (a)	Unsecured, unguaranteed, not impaired
Interest Bearing	—	—	—	Interest-bearing, to be paid in cash (b)	Unsecured, unguaranteed, not impaired
	2,384,654	25,560,700	27,945,354		

(a) Non-interest-bearing Advances from shareholders

In the special meeting of the Board held last May 7, 2017, the directors and shareholders were mandated and empowered to contribute resources and make cash advances to the Company for the development of its medical structures and appurtenances. In view of this, the shareholders advanced the monies in support of the Company's building construction requirements. These advances are non-interest bearing and to be paid subject to availability of funds and/or the Board may decide to convert said advances to equity in the distant future. The Company, however, also reserves the right to defer settlement and prioritize completion of the hospital building.

(b) Interest-bearing Advances from shareholders

On June 3, 2019, the Company acquired an unsecured interest-bearing advance from the shareholders at 12% per annum which was primarily used by the Company to support the working capital requirement during the start of its operation. The Company, however, reserves the right to defer settlement in favor of prioritizing payments relative to hospital construction. Total finance costs on these loans amounted to nil, ₱896,230 and ₱1,402,619 in 2024, 2023 and 2022, respectively.

(c) There is no transaction with promoters for the past 5 years.

Family Relationships

Among the directors and officers of Allied Care Experts (ACE) Dumaguete Doctors, Inc., the assistant corporate treasurer, Michael Edward Enriquez, is the son of Dr. Amado Manuel Enriquez, Jr. a member of the Board of Directors.

F. Management and Certain Security Holders

Directors, Executive Officers

There are fifteen (15) members of the Board, three (3) of whom are independent directors who hold office for one (1) year. The Corporation relies significantly on the continued collective efforts of its senior executive officers and expects each employee to do his share in achieving the Corporation's goals.

There are no family relationships up to the fourth civil degree either by consanguinity or affinity among directors, executive officers, persons nominated or chosen by the company to become directors, or executive officers, any security holder of certain record, beneficial owner or management.

As of April 30, 2025, none of the nominees for election as director, executive officer, underwriter or control person of the registrant has been involved in the following: (1) Bankruptcy; (2) Conviction by final judgment; (3) Being subject to any Order, Judgment or Decree; and (4) Violation of Securities or Commodities Law.

G. Corporate Governance

The Company adheres to the principles of good governance as provided in its Manual on Corporate Governance (MCG). In the performance of their respective responsibilities, the directors, officers and employees are guided by the mission and vision of the Company and the good corporate practices provided under the Company's Manual on Corporate Governance.

The Board has created different committees: Nomination and Election Committee, Audit Committees, Remuneration/Compensation Committee, Committee on Corporate Governance and Committee on Inspection and Validity of Proxies, all composed of qualified members and who undertake their functions as mandated. There were no major deviations from the adopted Manual on Corporate Governance.

The Independent directors have submitted their Certificates of Qualification as required by the SEC vis-à-vis Section 38 of the Securities Regulation Code. The Corporation has filed its Manual on Corporate Governance on June 30, 2023.

The independent directors have submitted their Certificate of Qualification as required by the SEC vis-à-vis Section 38 of the Securities Regulation Code.

ANNEX “C”

**TOP 20 STOCKHOLDERS
As of March 31, 2025**

NAME		NATIONALITY	TYPE	NUMBER OF SHARES	% OF OWNERSHIP
1.	Amado Manuel C. Enriquez Jr.	Filipino	Common	12,450	7.41%
			Founder	50	
			TOTAL	12,500	
2.	Marietta T. Samoy	Filipino	Common	7,470	4.45%
			Founder	30	
			TOTAL	7,500	
3.	Geanie A. Cerna-Lopez	Filipino	Common	4,980	2.57%
			Founder	20	
			TOTAL	5,000	
4.	Daphne R. Rana	Filipino	Common	3,120	1.86%
			Founder	10	
			TOTAL	3,130	
5.	Felicisimo D. De Castro	Filipino	Common	2,490	1.48%
			Founder	10	
			TOTAL	2,500	
6.	Brenda V. Diputado	Filipino	Common	2,490	1.48%
			Founder	10	
			TOTAL	2,500	
7.	Junabeth C. Credo	Filipino	Common	2,490	1.48%
			Founder	10	
			TOTAL	2,500	
8.	Aejeleth B. Eyas	Filipino	Common	2,490	1.48%
			Founder	10	
			TOTAL	2,500	
9.	Felix P. Nolasco	Filipino	Common	2,490	1.48%
			Founder	10	
			TOTAL	2,500	
10.	Generoso M. Orillaza	Filipino	Common	2,490	1.48%
			Founder	10	
			TOTAL	2,500	
11.	Ronald L. Ramiro	Filipino	Common	2,490	1.48%
			Founder	10	
			TOTAL	2,500	
12.	Roy Diamond M. Arco	Filipino	Common	2,490	1.48%
			Founder	10	
			TOTAL	2,500	

13.	Rolando E. Regalado	Filipino	Common	2,490	1.48%
			Founder	10	
			TOTAL	2,500	
14.	Angelo Alcala	Filipino	Common	2,490	1.48%
			Founder	10	
			TOTAL	2,500	
15.	Idelle Marie A. Yurong	Filipino	Common	2,490	1.48%
			Founder	10	
			TOTAL	2,500	
16.	Angelo Michael A. Singco	Filipino	Common	2,490	1.48%
			Founder	10	
			TOTAL	2,500	
17.	Aideline E. Sison	Filipino	Common	2,490	1.48%
			Founder	10	
			TOTAL	2,500	
18.	Brian Joseph M. Calinawagan	Filipino	Common	2,490	1.48%
			Founder	10	
			TOTAL	2,500	
19.	Maria Rhodora G. De Leon	Filipino	Common	2,490	1.48%
			Founder	10	
			TOTAL	2,500	
20.	Michael Edward R. Enriquez	Filipino	Common	2,490	1.48%
			Founder	10	
			TOTAL	2,500	

ANNEX “D”

**LIST OF THE DIRECTORS, OFFICERS AND STOCKHOLDERS WHO ATTENDED THE
Y2024 ANNUAL STOCKHOLDERS' MEETING**

- | | |
|--------------------------------------|---------------------------------------|
| 1. Dr. Aejeleth B. Eyas | 37. Dr. Marissa A. Orillaza |
| 2. Dr. Aideline E. Sison | 38. Dr. Mark Joseph C. Lopez |
| 3. Dr. Amado Manuel C. Enriquez Jr. | 39. Dr. Michael Edward R. Enriquez |
| 4. Dr. Angelo L. Alcala | 40. Dr. Miguel R. Enriquez |
| 5. Dr. Angelo Michael A. Singco | 41. Dr. Nailani Z. Tan |
| 6. Dr. Bernie A. Orhel | 42. Dr. Nestor Jogie C. Arroyo |
| 7. Dr. Brenda V. Diputado | 43. Dr. Pal K. Amante |
| 8. Dr. Brian Joseph M. Calinawagan | 44. Dr. Raponzel Josephine A. Fontelo |
| 9. Dr. Camelo R. Domingo Jr. | 45. Dr. Revey S. Nuico |
| 10. Dr. Carlos M. De La Rosa | 46. Dr. Robert H. Tan |
| 11. Dr. Concepcion P. Rosario | 47. Dr. Roberto M. De Leon |
| 12. Dr. Corazon D. Uy | 48. Dr. Rolando E. Regalado |
| 13. Dr. Daphne Lyn R. Rana | 49. Dr. Ronald I. Ramiro |
| 14. Dr. Daryl M. Apla-on | 50. Dr. Roy Diamond M. Arco |
| 15. Dr. Esmeralda V. De La Rosa | 51. Dr. Silahis O. Rosario |
| 16. Dr. Eulena P. Nolasco | 52. Dr. Ver Emerald M. Arco |
| 17. Dr. Evangeline Y. Zozobrado | 53. Ernst Cesar R. Rana |
| 18. Dr. Felicisimo D. De Castro | 54. Felino Cerna |
| 19. Dr. Felix P. Nolasco | 55. Windie A. Aba |
| 20. Dr. Franciene P. Vasquez | 56. Eva Mae V. Ablir |
| 21. Dr. Geanie A. Cerna-Lopez | 57. Joy B. Adalia |
| 22. Engr. Generoso M. Orillaza | 58. Emmanuel Joseph Adlaon |
| 23. Dr. Glenda N. Nuico | 59. Christiane Allen A. Alviola |
| 24. Dr. Idelle Marie A. Yurong | 60. Faith C. Amistoso |
| 25. Dr. Jane R. Ramiro | 61. Jore G. Amistoso |
| 26. Dr. Jennifer P. Emperado | 62. Renato S. Añasco |
| 27. Dr. Jonathan C. Amante | 63. Atty. Myla Amboy |
| 28. Dr. Junabeth C. Credo | 64. Jucille Ann C. Austero |
| 29. Dr. Karen Mae A. Sayson | 65. Melanie Mae O. Austero |
| 30. Dr. Lynn L. Olegario | 66. Claudette M. Balonglong |
| 31. Dr. Maita C. Cruz | 67. Karen M. Caminos |
| 32. Dr. Maria Carmelita N. Vera Cruz | 68. Mary Joy M. Candelario |
| 33. Dr. Maria Rhodora G. De Leon | 69. Reinelda C. Cheng |
| 34. Dr. Marietta T. Samoy | 70. Matheau Flo A. Chia |
| 35. Dr. Marilou R. Enriquez | 71. Lucille L. Credo |
| 36. Dr. Marilyn R. Enriquez | 72. Neil Vic A. Divinagracia |

73. Rejjine Zaneta S. Divinagracia
74. Teodorico V. Dominado
75. Fritzie P. Doyongan
76. Aniethelia M. Du
77. Paulina S. Duran
78. Janerisa A. Edjec
79. Robert Anthony L. Edjec
80. Imelda C. Electona
81. Janice Fay A. Enardecido
82. Micah B. Enardecido
83. Charmaine A. Enriquez
84. Teresa M. Estorco
85. Cresman D. Eyas
86. Peregrino Jr. B. Flores
87. Joel E. Folio
88. Reegine Mae A. Gamu
89. Bimchil Dierdre B. Go
90. Esmeralda T. Gomez
91. Adriano A. Gregorio
92. Honey Mae R. Grepon
93. Jeffrey D. Lasmarias
94. Aldin A. Legaspi
95. Clyde Me P. Limpiado
96. Grace Therese A. Logronio
97. Tulip F. Lopez
98. Jesse N. Macias
99. Daphne Christine C. Malicay
100. Ranvil Joseph Egon Mallonga
101. Florence D. Martin
102. Jezille A. Martinez
103. Lucille S. Martinez
104. Jessie E. Mascardo
105. Ariel V. Merquita
106. Katherine Joy P. Merquita
107. Lope G. Noay
108. Nora Maria Elena Osmeña
109. Denver A. Pareja
110. Daryl Hannah V. Parrilla
111. Gerick Bryann I. Pasana
112. Dizire S. Patun-Og
113. Jay T. Pontillas
114. Robb R. Rana
115. Fe Jane F. Rodriguez
116. Gabriel M. Sanson
117. Senen Joy T. Selarta
118. Noemi Q. Sun
119. Emmanuel Surban
120. Andrews F. Taala
121. Carolyn A. Tabaloc
122. Fairie C. Tale
123. Geraldine F. Tan
124. Elsie V. Teves
125. Ian C. Tonelete
126. Araceli P. Tumacole
127. Walden R. Ursos
128. Jesusa D. Vailoces
129. Maria Leila L. Villaflores
130. Love T. Villareal
131. Je M. Ygnalaga
132. Reynald S. Zamora

ANNEX “E”

ATTENDANCE OF DIRECTORS

Name of Director	January 11, 2024	February 8, 2024	March 14, 2024	April 8, 2024	April 11, 2024	April 24, 2024	May 9, 2024	June 13, 2024	July 2, 2024	July 11, 2024	August 8, 2024	September 12, 2024	October 10, 2024	November 14, 2024	November 28, 2024	December 12, 2024	% of Attendance
Dr. Amado Manuel C. Enriquez Jr.	P	P	P	P	P	P	P	P	P	P	P	P	P	P	P	P	100%
Dr. Geanie Cerna-Lopez	P	P	P	P	P	P	P	P	P	P	P	P	P	P	P	P	100%
Dr. Jonathan Amante	P	A	A	P	P	A	P	P	A	A	P	A	A	A	A	A	38%
Dr. Robert H. Tan	P	P	P	P	P	P	P	P	P	P	P	P	P	P	P	P	100%
Dr. Marietta Samoy	P	P	P	P	P	P	P	P	P	P	P	P	P	P	P	P	100%
Dr. Aejeleth Eyas	NYAD	NYAD	NYAD	NYAD	NYAD	NYAD	NYAD	NYAD	P	P	P	P	P	P	P	P	100%
Dr. Ronald Ramiro	NYAD	NYAD	NYAD	NYAD	NYAD	NYAD	NYAD	NYAD	P	P	P	P	P	A	P	P	88%
Dr. Roy Diamond Arco	NYAD	NYAD	NYAD	NYAD	NYAD	NYAD	NYAD	NYAD	P	P	P	P	P	P	P	P	100%
Dr. Aideline Sison	P	P	P	A	A	P	P	P	NLAD	NLAD	NLAD	NLAD	NLAD	NLAD	NLAD	NLAD	75%
Dr. Daryl Aplon	P	P	P	P	P	A	P	P	NLAD	NLAD	NLAD	NLAD	NLAD	NLAD	NLAD	NLAD	88%
Mr. Carlos De La Rosa	NYAD	NYAD	NYAD	NYAD	NYAD	NYAD	NYAD	NYAD	P	P	P	P	P	P	P	P	100%
Dr. Corazon Uy	NYAD	NYAD	NYAD	NYAD	NYAD	NYAD	NYAD	NYAD	A	A	P	P	P	P	P	P	75%
Dr. Roberto De Leon	P	P	P	P	P	P	P	A	P	P	P	A	A	P	A	A	69%
Dr. Glenda Nuico	NYAD	NYAD	NYAD	NYAD	NYAD	NYAD	NYAD	NYAD	P	A	P	P	P	P	P	P	88%
Dr. Rolando Regalado (ID)	NYAD	NYAD	NYAD	NYAD	NYAD	NYAD	NYAD	NYAD	P	P	P	P	P	P	P	P	100%
Engr. Generoso Orillaza (ID)	NYAD	NYAD	NYAD	NYAD	NYAD	NYAD	NYAD	NYAD	P	P	P	P	P	P	P	P	100%
Dr. Evangeline Zozobrado (ID)	NYAD	NYAD	NYAD	NYAD	NYAD	NYAD	NYAD	NYAD	P	P	P	A	P	P	P	P	88%
Dr. Felix Nolasco	P	P	P	P	P	P	P	A	NLAD	NLAD	NLAD	NLAD	NLAD	NLAD	NLAD	NLAD	88%
Dr. Michael Angelo Singco	A	A	P	P	P	P	P	P	NLAD	NLAD	NLAD	NLAD	NLAD	NLAD	NLAD	NLAD	75%
Dr. Silahis Rosario	P	P	P	P	P	P	A	P	NLAD	NLAD	NLAD	NLAD	NLAD	NLAD	NLAD	NLAD	88%
Dr. Felicísimo De Castro	P	A	P	A	A	A	A	P	NLAD	NLAD	NLAD	NLAD	NLAD	NLAD	NLAD	NLAD	38%
Dr. Maria Carmelita Vera Cruz (ID)	P	P	P	P	A	P	A	P	NLAD	NLAD	NLAD	NLAD	NLAD	NLAD	NLAD	NLAD	75%
Dr. Angelo Alcala (ID)	P	P	P	P	P		P	P	NLAD	NLAD	NLAD	NLAD	NLAD	NLAD	NLAD	NLAD	100%
Dr. Nestor Jogie Arroyo (ID)	P	P	P	A	P	P	P	P	NLAD	NLAD	NLAD	NLAD	NLAD	NLAD	NLAD	NLAD	88%

Legend: P – Present ; A – Absent; NYAD – Not Yet A Director; NLAD – No Longer A Director

CERTIFICATION OF INDEPENDENT DIRECTOR

I, Generoso M. Orillaza, Filipino, of legal age and a resident of Mother Ignacia Ave, South Triangle, Quezon City having been duly sworn in accordance with law do hereby declare that:

1. I am a nominee for independent director of ALLIED CARE EXPERTS (ACE) DUMAGUETE DOCTORS, INC and have been its independent director since JULY 2024.
2. I am affiliated with the following companies or organizations (including government-owned and controlled corporations):

Company/Organization	Position/Relationship	Period of Service
ACE Baypointe Hospital and Medical Center	Member, Board of Director	March 2024 to present
ACE Medical Center Cebu	Independent Director	July 2024 to present
Unihealth Paranaque Hospital and Medical Center	Head, Eng'g. and Maintenance	July 2023 to present
ACE Medical Center Gensan	Member, Construction Committee	Aug 2016 to present
St. Lawrence of Balagtas Medical Center	Member, Construction Committee	Jan 2022 to present

3. I possess all the qualifications and none of the disqualifications to serve as an Independent Director of ALLIED CARE EXPERTS (ACE) DUMAGUETE DOCTORS, INC, as provided for in Section 38 of the Securities Regulation Code, its Implementing Rules and Regulations and other SEC issuances
4. I am related to the following director/officer/substantial shareholder of N/A other than the relationship provided under Rule 38.2.3 of the Securities Regulation Code

Name of Director/Officer/Substantial Shareholder	Company	Nature of Relationship
N/A	N/A	N/A

5. To the best of my knowledge, I am not the subject of any pending criminal or administrative investigation or proceeding/ I disclose that I am the subject of the following criminal/administrative investigation or proceeding (as the case may be);
6. (For those in government service/affiliated with a government agency or GCC) I have the required written permission or consent from the (head of agency/department) to be an independent director in N/A, pursuant to Office f the President Memorandum Circular No. 17 and Section 12, Rule XVIII of the Revised Civil Service Rules
7. I shall faithfully and diligently comply with my duties and responsibilities as independent director under the Securities Regulation Code and its Implementing Rules and Regulations, Code of Corporate Governance and other SEC issuances

8. I shall inform the Corporate Secretary of ALLIED CARE EXPERTS (ACE) DUMAGUETE DOCTORS, INC. of any changes in the above mentioned information within five days from its occurrence.


Done this 30th day of April 2025, at Quezon City.


GENEROSO M. ORILLAZA

Affiant

SUBSCRIBED AND SWORN to before me this 09 day of MAY 2025, at QUEZON CITY affiant personally appeared before me and exhibited to me his/her _____ issued on _____, at _____

Doc No 119
Page No 35
Book No 63
Series of 2025


ATTY. CONCEPCION P. VILLAREÑA
Notary Public for Quezon City
Until December 31, 2025
PTR No. 6989624 / January 2, 2025 Q.C.
IBP No. 461667 / October 29, 2024 Q.C.
Roll No. 30457 / 05-09-1980
MCLE VII-0006994 / 09-21-2021
ADM. MATTER No. NP-021 (2024-2025)
TIN No. 131-942-754

CERTIFICATION OF INDEPENDENT DIRECTOR

1. D. Evelyn R. Nolasco, MBA Filipino, of legal age and a resident of Barangay 8 BAY View, Marikina City having been duly sworn in accordance with law do hereby declare that:

1. I am a nominee for independent director of ACE Remigios Dato Inc. and have been its independent director since N.A.
2. I am affiliated with the following companies or organizations (including government-owned and controlled corporations):

Company/Organization	Position/Relationship	Period of Service
<u>STO A.M.C.</u>	<u>Director</u>	<u>2018 present</u>
<u>QUMC/</u>	<u>Director</u>	<u>2019 "</u>
<u>Prim Pasig MCIP</u>	<u>Director</u>	<u>2019 "</u>

3. I possess all the qualifications and none of the disqualifications to serve as an Independent Director of ACE Remigios Dato Inc., as provided for in Section 38 of the Securities Regulation Code, its Implementing Rules and Regulations and other SEC issuances

4. I am related to the following director/officer/substantial shareholder of N.A. other than the relationship provided under Rule 38.2.3 of the Securities Regulation Code

Name of Director/Officer/Substantial Shareholder	Company	Nature of Relationship
<u>N.A.</u>	<u>N.A.</u>	<u>N.A.</u>

5. To the best of my knowledge, I am not the subject of any pending criminal or administrative investigation or proceeding/ I disclose that I am the subject of the following criminal/administrative investigation or proceeding (as the case may be);
6. (For those in government service/affiliated with a government agency or GCC) I have the required written permission or consent from the (head of agency/department) to be an independent director in N.A. pursuant to Office f the President Memorandum Circular No. 17 and Section 12, Rule XVIII of the Revised Civil Service Rules
7. I shall faithfully and diligently comply with my duties and responsibilities as independent director under the Securities Regulation Code and its Implementing Rules and Regulations, Code of Corporate Governance and other SEC issuances

8. I shall inform the Corporate Secretary of _____ of any changes in the abovementioned information within five days from its occurrence.

Done this MAY 05 2025 at MUNTINLUPA CITY.


[Signature]

Affiant

SUBSCRIBED AND SWORN to before me this MAY 05 2025 at

MUNTINLUPA CITY affiant personally appeared before me and exhibited to me his/her

OSCE- Muntinlupa 216107 issued on _____ at _____



[Signature]
ATTY. CARMELITA R. BACULIO
NOTARY PUBLIC FOR MUNTINLUPA CITY
Notarial Commission No. 24-006 until 31 December 2025
Unit 902 Primeland Bldg., 2218 Market St.,
Madrigal Business Park, Muntinlupa City
IBP Lifetime No. 010762 Roll No. 61148
PTR No. 4763717 01/02/2023
MCLE VIII-0015240 April 20, 2020

CERTIFICATION OF INDEPENDENT DIRECTOR

I, Concepcion P. Rosario, Filipino, of legal age and a resident of Tiongson St. West Drive, Daro, Duamguete City, having been duly sworn in accordance with law do hereby declare that:

1. I am a nominee for independent director of Allied Care Experts (ACE) Dumaguete Doctors Inc., and have been its independent director since N/A.
2. I am affiliated with the following companies or organizations (including government-owned and controlled corporations):

Company/Organization	Position/Relationship	Period of Service
N/A		

3. I possess all the qualifications and none of the disqualifications to serve as an Independent Director of Allied Care Experts (ACE) Dumaguete Doctors Inc., as provided for in Section 38 of the Securities Regulation Code, its Implementing Rules and Regulations and other SEC issuances
4. I am related to the following director/officer/substantial shareholder of N/A other than the relationship provided under Rule 38.2.3 of the Securities Regulation Code

Name of Director/Officer/Substantial Shareholder	Company	Nature of Relationship
N/A		

5. To the best of my knowledge, I am not the subject of any pending criminal or administrative investigation or proceeding/ I disclose that I am the subject of the following criminal/administrative investigation or proceeding (as the case may be);
6. (For those in government service/affiliated with a government agency or GCC) I have the required written permission or consent from the (head of agency/department) to be an independent director in N/A, pursuant to Office of the President Memorandum Circular No. 17 and Section 12, Rule XVIII of the Revised Civil Service Rules
7. I shall faithfully and diligently comply with my duties and responsibilities as independent director under the Securities Regulation Code and its Implementing Rules and Regulations, Code of Corporate Governance and other SEC issuances
8. I shall inform the Corporate Secretary of Allied Care Experts (ACE) Dumaguete Doctors Inc. of any changes in the abovementioned information within five days from its occurrence.

[Signature]

Done this 07 MAY 2025 day of _____, at Dumaguete City.

[Signature]

Affiant

SUBSCRIBED AND SWORN to before me this 07 MAY 2025 day of _____, at Dumaguete City, affiant personally appeared before me and exhibited to me his/her _____ issued on _____, at _____.

Doc No 170
Page No 35
Book No 11
Series of 2025


[Signature]
ATTY. JULIUS ANTHONY R. CUENCO, CPA
Notary Public for Dumaguete City, Siaton,
Valencia, Zamboanga City, Bacang, and
Sibulan, Province of Negros Oriental
Serial No. 2025-016, Until [blank] 2026
Room 405, Silliman Portal West Bldg., Dumaguete City
Roll of Attorneys No. 75804
PTR No. 4319858A / Jan. 2, 2025 Negros Oriental
IBP No. 355389, 470909 / Oct. 9, 2024 Pasig
MCLE Compliance No. VIII-0008051

CERTIFICATION

This is to certify that the directors, officers, and the nominees for board of directors for year 2025-2026, of Allied Care Experts (ACE) Dumaguete Doctors Inc., are not connected with any government agencies or its instrumentalities.

30 MAY 2025


Issued this ___ day of May 2025 at Dumaguete City, Philippines.




AEJELETH B. EYAS
Corporate Secretary

SUBSCRIBED AND SWORN TO BEFORE ME, a Notary Public, for and in the City of Dumaguete City, Philippines, this ___ day of May 2025, affiant presented to me her Professional Regulation Commission ID No. _____, issued on _____.

NOTARY PUBLIC



ATTY. JULIUS ANTHONY R. CUENCO, CPA
Notary Public for Dumaguete City, Siaton,
Valencia, Zamboanguita, Dauin, Bacong, and
Sibulan, Province of Negros Oriental
Serial No. 2025-016, Until Dec. 31, 2026
Room 405, Silliman Portal West Bldg., Dumaguete City
Roll of Attorneys No. 75804
PTR No. 4319858A / Jan. 2, 2025 Negros Oriental
IBP No. 355389, 470909 / Oct. 9, 2024 Pasig City
MCLE Compliance No. VIII-0008051



Doc No. 108
Page No. 35
Book No. 11
Series of 2025